Podcasts about hematology ash

Join Dr. Madanat (UT Southwestern, Texas), Dr. Stahl (Harvard Medical School, Massachusetts), and Dr. Papadantonakis (Emory University, Georgia) as they break down key Myelodysplastic Syndromes (MDS) abstracts from the 2024 American Society of Hematology (ASH) meeting.Tune in to gain valuable insights and stay informed about the evolving landscape of MDS management.

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH)... The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.

In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics, a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology. He has more than 15 years of research and teaching experience in Bone Marrow Transplant (BMT)/Cellular Therapies and more than 10 years of industry experience. He was the Program Lead for early-stage assets at Nektar and manages clinical trial programs from Phase I through to Phase III. Dr. Marcondes is a member of multiple professional clinical and translational research organizations, including the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research (AACR) and Center for International Blood & Marrow Transplant Research (CIBMTR). Listen to the episode to hear about the current research landscape in autoimmune disorders, including the work Dr. Marcondes is leading at Nektar Therapeutics. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)... The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.

The involvement of oncology fellows in state policy and advocacy efforts is essential for enhancing cancer care and advancing research. The Association of Cancer Care Centers (ACCC) provides up-to-date information and opportunities for oncology advocacy, helping oncologists early in their career to be aware of how to contribute to local, state, and national initiatives. In this episode, CANCER BUZZ speaks with Katherine Baker, MD, medical director of value-based care and medical oncologist at Tennessee Oncology, to discuss her experience in engaging in advocacy efforts with the American Society of Hematology (ASH), the Community Oncology Alliance (COA), and her current role as a board member on the Tennessee Oncology Practice Society (TOPS) advocacy committee. We also hear from Haley M Simpson, MD, PhD, physician-scientist, Division of Hematology at the University of Colorado, about the direct impact of advocacy on patient care.   “To me, forming coalitions through these [national] organizations is essential for driving meaningful, long lasting policy change, as collective voices are often much stronger and more impactful than individual efforts on your own.” -Katherine Baker, MD   “By getting involved in advocacy and policy earlier in your career, it has all the more ability to amplify the impact for patients.” -Haley Simpson, MD, PhD   Katherine Baker, MD, MMHC Medical Director of Value-Based Care and Medical Oncologist Tennessee Oncology Nashville, TN   Haley M. Simpson, MD, PhD Physician-Scientist, Division of Hematology University of Colorado Aurora, CO   This podcast is part of the Oncology State Societies (OSS) Policy and Advocacy program, made possible through the support of Johnson & Johnson.   Please visit your state society's website for potential fellowship opportunities, which you can find here. For any questions or to learn about upcoming events and opportunities, feel free to email Amanda Impellizzeri directly at aimpellizzeri@accc-cancer.org.   Resources ACCC and OSS Advocacy Engagement Initiative  ACCC Legislative Action Center  NCCN Policy Fellows Program  ASCO Advocacy Resources  ASCO Fellows Resources

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive advantage in multiple myeloma. Meanwhile, Vertex unveiled positive long-term data for its CRISPR Therapeutics–partnered gene therapy Casgevy in sickle cell disease—results BMO Capital Markets analysts said should help Casgevy keep its edge over bluebird bio's Lyfgenia. On that note, Casgevy and Lyfgenia have a new outcomes-based payment model after the Centers for Medicare and Medicaid Service (CMS) said both companies have agreed to participate in a voluntary program to improve access to the gene therapies. Speaking of access, Eli Lilly and Novo Nordisk both announced significant manufacturing investments aimed at shoring up production of their diabetes and weight loss blockbusters tirzepatide and semaglutide. And in related news, the European Commission gave its blessing to Novo Holdings' controversial acquisition of contract manufacturing firm Catalent. Elsewhere, AbbVie got a much-needed win for Cerevel-acquired Parkinson's disease therapy tavapadon—a month after the deal's cornerstone asset emraclidine failed in schizophrenia—while uniQure announced it has aligned with the FDA on “key elements” of the accelerated approval pathway for its investigational gene therapy for Huntington's, AMT-130.

On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump's pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry.The BioCentury team then discusses its analysis of abstracts released ahead of the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlighting methods for applying dual or bispecific CAR T cell designs to solid tumors. And they also analyze FDA approvals of products by biotech companies, noting that current trends show biotechs shedding their reliance on pharma to get drugs across the finish line for approval.View full story: https://www.biocentury.com/article/65436300:00 - Introduction01:08 - Trump's NIH Pick12:13 - Multi-targeted CAR Ts19:26 - Biotech FDA ApprovalsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this Trendsetter Tuesday podcast, Meetings Today digital content coordinator Logan Pratt sat down with Bill Reed, Chief Event Strategy Offer for the American Society of Hematology (ASH) and one of this year's Meetings Trendsetters. Reed talks about his journey in the meetings industry to this point, why he is always asking questions and innovating and why he is never complacent with the status quo.

MDS experts Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss new trials presented in the last meeting of the American Society of Hematology (ASH) 2023. They focus on luspatercept, imetelstat and roxodustat.  

Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat, roxodustat and Ker-050.  

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024 Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

It wasn't even two weeks into the new year when the Food and Drug Administration made their first FDA approval. In this case, it was a Keytruda regimen for certain patients with gynecologic cancers. We at CURE® spoke with an the primary investigator on the study leading to the approval about what patients need to know about the latest new indication.  Also last week, we highlighted the Lymphedema Treatment Act and spoke to an expert about the new law.  Another story in the regulatory space: the FDA granted a Fast Track designation to speed up the review of a novel drug used to treat patients with relapsed or refractory CLL or SLL.  Finally, research from the American Cancer Society showed that Medicaid expansion states tended to have improved post-surgical outcomes in patients with non-small cell lung cancer.   Keytruda Plus CRT Offers ‘Better Chance of Cure' in Advanced Cervical Cancer The Food and Drug Administration has granted approval for Keytruda (pembrolizumab) in combination with chemoradiotherapy for the treatment of stages 3 to 4A cervical cancer, marking the first approval of an anti-PD-1 therapy with chemotherapy for this patient population and the third FDA approval for treating cervical cancer with Keytruda.  This week, I spoke with Dr. Linda R. Duska, a gynecologic oncologist and principal investigator on the study leading to the approval, who discussed the KEYNOTE-A18 trial, which enrolled 1,060 patients and demonstrated a 30% decrease in progression for those receiving the combination of Keytruda and chemotherapy. The overall survival data is not yet mature, but the treatment showed a 41% reduction in the risk of disease progression or death. While Dr. Duska emphasized that cervical cancer is preventable thanks to a safe and effective vaccine, she said that for patients with the disease, this new regimen is particularly exciting.  January is also Cervical Cancer Awareness month, so definitely stay tuned to curetoday.com for more of our coverage on the disease.  Medicare Must Now Cover Lymphedema Treatment Garments The Lymphedema Treatment Act, signed into federal law on Dec. 23, 2022, is now in effect as of Jan. 1, 2024, allowing Medicare coverage for doctor-prescribed compression supplies for patients experiencing. The bill encompasses standard and custom-fitted gradient compression garments and other approved items prescribed by healthcare professionals to treat lymphedema. Now basically what that means is that patients insured by Medicare Part B can now have their lymphedema garments covered by insurance.  This coverage is expected to ease financial burdens on patients, especially as these garments can be expensive.  I spoke with Joanna Fawzy Doran, CEO of Triage Cancer, who emphasized the importance of patient and provider awareness about coverage rights, appealing denials and navigating the process. Although the law does not mandate private insurers to cover compression sleeves for lymphedema patients, Doran noted that Medicare's coverage sets a precedent for broader access in the future. FDA Grants NX-5948 Fast Track Designation for R/R CLL, SLL The FDA has granted Fast Track designation to NX-5948, a novel drug, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously undergone two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.  Fast Track designation aims to expedite the development and review of drugs addressing serious conditions with unmet medical needs.  NX-5948 is currently in a Phase 1a/1b clinical trial, with initial findings presented at the 2023 American Society of Hematology (ASH) annual meeting indicating safety, tolerance, and clinical activity. The drug showed no dose-limiting toxicities or treatment-related side effects leading to discontinuation, and the most common side effects were purpura/contusion, nausea, and thrombocytopenia.  Medicaid Expansion May Decrease Early Mortality in Some With NSCLC States with Medicaid expansion tended to have a significant decrease in early, postoperative mortality from non-small cell lung cancer, according to recent research.  The research focused on nearly 15,000 patients undergoing surgery for NSCLC, with 62.1% residing in states supporting Medicaid expansion. The study found notable reductions in 30-day and 90-day postoperative mortality in patients with stages 1, 2, or 3 NSCLC in expansion states. Patients in non-expansion states were found to be younger, non-Hispanic Black, uninsured, and with comorbidities.  The study also evaluated changes in early mortality before and after the Affordable Care Act (ACA) implementation, showing a decrease in the 30-day mortality rate in expansion states from 0.97% to 0.26% after the ACA. Now, advocates, including the American Cancer Society, continue to emphasize the importance of expanding Medicaid eligibility to improve health outcomes.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate: - TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis - MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis - SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML - AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results   #ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: - ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p) - SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma - POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: - PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) - IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM - Bortezomib Dosing - Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM - KarMMA-3 Update - Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis

Signals from the Fed that rate cuts are on the way rallied biotech indexes last week, but is the uptick more than a blip? On the latest BioCentury This Week podcast, BioCentury's editors discuss how interest rate cuts could spur a risk-on rotation back into the sector by generalist investors, the possibility of biotech outperformance in 2024, and what it will take for the IPO window to open. They also assess progress demonstrated by companies' with next-generation gene editors at this year's American Society of Hematology (ASH) meeting, as well as BioCentury's analysis of new targets at the conference. The editors also offer their picks for the highlights (and lowlights) of 2023 and predictions for what's in store in the New Year.Music for the 24th Bio€quity Europe teaser produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty Images

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts

Good morning from Pharma and Biotech daily, the podcast bringing you crucial updates from the Pharma and Biotech world. Today's episode covers several significant developments and deals in the industry.AstraZeneca is on the verge of acquiring vaccine maker Icosavax for up to $1.1 billion. This move underscores AstraZeneca's dedication to vaccine development, particularly as it gains a combination vaccine targeting respiratory viruses. This acquisition is timely, considering the looming expiration of patents for several major medicines, a challenge prompting big pharma to explore new markets.In a notable development, Bristol Myers Squibb (BMS) has acquired rights to develop and commercialize Systimmune's antibody-drug conjugate (ADC) for various cancers, including lung and breast cancer. The deal, potentially worth $8.4 billion, highlights the growing interest in ADCs, a promising class of cancer treatments.Sanofi has terminated its licensing agreement with Maze Therapeutics for a Pompe disease drug following challenges from the US Federal Trade Commission (FTC). The decision to end this deal reflects the heightened regulatory scrutiny within the industry.Reiterating its focus on vaccines, AstraZeneca has also acquired Icosavax in a deal potentially worth $1.1 billion. This acquisition enables AstraZeneca to enter the market for respiratory syncytial virus vaccines, demonstrating its commitment to expanding its vaccine portfolio.In a major industry move, Pfizer's $43 billion acquisition of Seagen has overcome regulatory barriers and is set to conclude. This deal, the largest in recent years, will significantly enhance Pfizer's presence in the ADC market, a trend indicative of the current wave of large-scale acquisitions in pharma.Sino Biological, a biotech firm, has made strides in gene therapy by developing platforms for multi-pass transmembrane protein products. These advancements underscore the industry's progress in drug manufacturing technologies.Employee engagement is gaining importance in the sector, as illustrated by Kyowa Kirin's new program aimed at involving its workforce in shaping the company's future. This approach reflects a broader understanding of the role of employee involvement in fostering innovation and success.Tome Biosciences has launched with a significant funding of $213 million, focusing on genomic medicines, particularly in precision oncology. This move highlights the ongoing advancements in gene therapy and personalized medicine.At the American Society of Hematology (ASH) annual meeting, BMS and 2seventy Bio presented promising survival data for their CAR-T therapy, Abecma, used in treating multiple myeloma. This data points to the potential of CAR-T therapy in treating complex diseases.Novartis' iptacopan showed positive results in a Phase III study for an ultra-rare kidney disease. Coming shortly after FDA approval for another indication, this demonstrates progress in treating rare diseases.Catalent is seeking to expand in the GLP-1 market, used in treating type 2 diabetes, amid a revenue downturn and staff cuts. This move reflects the competitive nature of the diabetes treatment market.The Centers for Medicare and Medicaid Services (CMS) are preparing to announce the 'maximum fair price' for drugs under the Inflation Reduction Act's negotiation program. This impending decision is poised to be a pivotal pharmaceutical trend in 2024, with significant political and economic implications, especially considering the upcoming presidential election.The year 2023 saw four historic FDA approvals, including a vaccine for RSV and a drug for Alzheimer's disease, showcasing ongoing progress in drug development and healthcare.Bryter's insights have been instrumental in pharma's success in marketing rare disease treatments, highlighting the vital role of data analytics and strategic insights in effective marketin

Dr. John Leonard shares his list of the 10 most interesting lymphoma-related abstracts to be presented at the 2023 meeting of the American Society of Hematology (ASH). The ASH annual meeting brings together blood cancer experts from around the world to present the most exciting research in the field. This annual special episode features an in-depth look at this year's cutting-edge research and also features 5 “bonus” podcast-only abstract selections. Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

The Cancer Advances podcast is joined by Abhay Singh, MD, MPH, a physician with the Department of Hematology and Medical Oncology at Cleveland Clinic to talk about his study, which aimed to identify risk factors for secondary malignancy in breast cancer survivors. This study was presented at the American Society of Hematology (ASH) 2022 annual meeting. Listen as Dr. Singh explains how he explored the different risk factors, such as G-CSF exposure, how the CHIP Clinic might be able to monitor patients, and the long-term goal to figure out which therapies patients should try to avoid.

Featuring perspectives from Dr Jacob Laubach, including the following topics: Evolution of first-line treatment for multiple myeloma (MM) (0:00)  Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27) ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35) ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57) ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05) ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33) Bispecific antibody therapy administration and patient education (52:41) ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17) CME information and select publications

Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/MM).

Featuring a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.

Featuring an interview with Dr John Allan, including the following topics: •      Update on key studies of acalabrutinib in the front-line setting (0:00) •      Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) •      Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) •       Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) •      Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) •      Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) •      Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) •      Emerging data with novel Bcl-2 inhibitors (1:11:26) •      Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37) CME information and select publications

Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/CLL).

Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.

Aaron Gerds, MD, MS, a hematologist in Cleveland Clinic Cancer Center's Leukemia and Myeloid Disorders Program and Deputy Director for Clinical Research at the Taussig Cancer Institute joins the Cancer Advances podcast to talk about the MOMENTUM trial that was presented at the American Society of Hematology (ASH) 2022 annual meeting. Listen as Dr. Gerds discusses myelofibrosis, the differences between the trial results from 24 to 48 weeks, and the exciting new approaches that are coming to the field.

In this special episode, Chadi hosts his previous mentor from his days as a fellow at Northwestern: Martin Tallman, MD, previous president of the American Society of Hematology (ASH) and world renowned leukemia expert. Together, they discuss mentorship and what makes a good mentor, where Dr. Tallman's interest in leukemia came from and why he decided to begin his career in Seattle, his road to becoming an ASH president and how his day-to-day responsibilities changed after his election, reasons for becoming more active on MedTwitter, and the progression of leukemia treatment in 30+ years, along with much more. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Discussing practice-changing studies from the American Society of Hematology (ASH) 2022 with Dr. Aaron Goodman "Papa Heme", Associate Professor of Medicine at UC San Diego Health - San Diego Hospital. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com  

Dr. John Leonard shares his list of the 10 most interesting and impactful lymphoma and blood cancer abstracts to be presented at the 2022 meeting of the American Society of Hematology (ASH). This episode also features 5 “bonus” podcast-only abstract selections in addition to offering extra insight into one of this year's plenary sessions.Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.